Critics of the proposed 2028 tariff plan warn that it could trigger a healthcare affordability crisis for millions of Americans. Generic drugs are the backbone of the U.S. healthcare system, providing affordable treatment for conditions like heart disease, diabetes, and hypertension. By imposing taxes on these imports, the policy effectively creates a new tax on patients, as manufacturers will likely pass the increased costs directly to consumers and insurance providers.
Economists point out that the pharmaceutical supply chain is deeply integrated and cannot be easily or quickly moved. Building new manufacturing plants requires years of planning, massive capital investment, and specialized labor that may not be readily available. Forcing this transition through tariffs could lead to significant market instability and potential drug shortages if current suppliers exit the market before domestic capacity is fully operational.
There is also the risk of retaliatory trade measures. If the U.S. imposes tariffs on foreign-made drugs, other nations may respond with their own trade barriers on American exports. This could escalate into a broader trade war that hurts multiple sectors of the economy, including agriculture and technology. Such a scenario would create a net negative for the economy, potentially offsetting any gains made in the pharmaceutical sector.
Finally, opponents argue that the focus should be on lowering drug prices rather than raising them. Instead of protectionist measures that increase costs, they suggest that the government should invest in research and development or streamline the approval process for new generic competitors. By prioritizing market competition over tariffs, the U.S. could achieve lower prices without endangering the supply of essential medications that patients rely on every day.